相关性贫血对晚期乳腺癌患者化疗疗效及预后的影响

Effect of Treatment-related Anemia on Chemotherapy Response and Prognosis in Patients With Advanced Breast Cancer

在晚期乳腺癌的治疗过程中骨髓抑制引起的贫血发生于在肿瘤治疗的整个过程,其发生与肿瘤类型、大小、化疗方案剂量、分期等因素密切相关。晚期乳腺癌治疗过程中贫血发病率较高。相关性贫血会降低治疗效果,缩短患者的生存时间,增加死亡风险。肿瘤相关性贫血的发病机制错综复杂,可能与肿瘤本身及治疗手段引起的骨髓抑制等因素有关。晚期乳腺癌相关性贫血的治疗目标为“预防并降低贫血的发生,提高治疗效果,改善预后”。更重要的是抑制肿瘤低氧微环境所导致的肿瘤恶化进程,从而提高治疗效果,改善预后。

Related treatments lead to anemia caused by myelosuppression in the treatment of patients with advanced breast cancer.It occurs in the whole process of tumor treatment,and its occurrence is closely related to factors such as tumor type,size,dose of chemotherapy regimen,and staging.The tumors with higher incidence of anemia.Related anemia can reduce the therapeutic effect,shorten the survival time of cancer patients,and increase the risk of death.The pathogenesis of tumor-associated anemia is complicated,which may be related to the tumor itself and the bone marrow suppression caused by treatment.The treatment goal of advanced breast cancerrelated anemia is“to prevent and reduce the occurrence of anemia,improve the therapeutic effect,and improve the prognosis.”It is more important to inhibit the progression of tumor progression caused by the tumor hypoxic microenvironment,thereby improving the therapeutic effect and improving the prognosis.